Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
SELECT extended these findings to people with obesity without diabetes, and FLOW showed kidney protection
& Luo, J
8 Building these skills and habits during treatment is crucial for long-term success and maintenance, particularly if the medication is eventually discontinued
US$ 24.97
US$ 22.82
US$ 20.20
&srotate=0)
US$ 21.80
